Phase II safetty and efficacy study of Actalycabtagene Autoleucel in relapsed\refractory B-Cell Malignancies
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Talicabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
Most Recent Events
- 30 Jan 2024 New trial record
- 12 Dec 2023 Pooled results from Phase I and a planned interim analysis of the Phase II study evaluating Actaly-celpresented at the 65th American Society of Hematology Annual Meeting and Exposition